首页> 外文期刊>Biomaterials >Drug release from starch-acetate microparticles and films with and without incorporated alpha-amylase.
【24h】

Drug release from starch-acetate microparticles and films with and without incorporated alpha-amylase.

机译:在有和没有掺入α-淀粉酶的情况下,药物从淀粉乙酸酯微粒和薄膜中释放出来。

获取原文
获取原文并翻译 | 示例
           

摘要

Acetylation of starch considerably decreases its swelling and enzymatic degradation. Thus, starch-acetate (SA) based delivery systems may be suitable for controlled drug delivery. The aim of the present study was to evaluate drug release from the SA microparticles (SA mps) and SA films. The average degree of acetyl substitution (DS) per glucose residue in the starch was either 1.9 (SA DS 1.9) or 2.6 (SA DS 2.6). Timolol (mw 332), calcein (mw 623) and bovine serum albumin (BSA, mw 68,000) were used as model drugs. A continuous timolol release from the both SA mps was observed in phosphate buffer solution (PBS) pH 7.4 (50-days incubation). The release of timolol was faster from the SA DS 1.9mps than from the SA DS 2.6mps. Calcein release from both SA mps was continuous in PBS pH 7.4 (5-days incubation). But, calcein release profile from the SA DS 2.6 film in PBS pH 7.4 showed discontinuities. However, the release of calcein from both SA films was continuous in human serum in vitro during the 7-day incubation, i.e. enzymes enhanced calcein release. Thus, alpha-amylase was incorporated into the SA films in order to enhance drug release from the films. However, the effects of incorporation of alpha-amylase on the model macromolecule (BSA) release from the SA films were modest. In conclusion, this study demonstrates the achievement of slow release of different molecular weight model drugs from the SA mps and films as compared to fast release from the native starch preparations. DS of SA, physicochemical properties of a drug and the presence of enzymes can all affect drug release profiles from SA based preparations.
机译:淀粉的乙酰化大大降低了其溶胀和酶促降解。因此,基于乙酸淀粉(SA)的递送系统可能适用于受控的药物递送。本研究的目的是评估药物从SA微粒(SA mps)和SA膜的释放。淀粉中每个葡萄糖残基的平均乙酰基取代度(DS)为1.9(SA DS 1.9)或2.6(SA DS 2.6)。替莫洛尔(mw 332),钙黄绿素(mw 623)和牛血清白蛋白(BSA,mw 68,000)被用作模型药物。在pH 7.4的磷酸盐缓冲溶液(PBS)(孵育50天)中观察到从两个SA mp连续释放噻吗洛尔。 SA DS 1.9mps中的噻吗洛尔释放速度快于SA DS 2.6mps中的释放速度。从两个SA mp中释放钙黄绿素在PBS pH 7.4中连续孵育(孵育5天)。但是,在PBS pH 7.4中SADS 2.6膜的钙黄绿素释放曲线显示出不连续性。然而,在7天的温育过程中,钙黄绿素从两个SA膜的释放在人血清中在体外是连续的,即酶增强了钙黄绿素的释放。因此,将α-淀粉酶掺入SA膜中以增强药物从膜中的释放。但是,掺入α-淀粉酶对从SA膜释放的模型大分子(BSA)的影响是适度的。总而言之,这项研究表明与从天然淀粉制剂中快速释放相比,从SA mps和薄膜中缓慢释放不同分子量模型药物的成就。 SA的DS,药物的理化性质和酶的存在都会影响基于SA的制剂的药物释放曲线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号